Search Results

You are looking at 1 - 10 of 1,318 items :

  • "acute coronary syndrome" x
Clear All

REFERENCES 1. Kumar A, Cannon CP. Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc 2009; 84(10): 917–38. 2. Boden H, van der Hoeven BL, Karalis I, Schalij MJ, Jukema JW. Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. J Intern Med 2012; 271(6): 521–36. 3. Patel NK, Elmariah S. Acute Coronary Syndromes. In: Lau JF, Barnes GD, Streiff MB, editors. Anticoagulation Therapy. Cham: Springer International Publishing; 2018. p. 197–216. 4. Dhoble A, Anderson HV

Clin Chem Lab Med 2010;48(9):1339–1343 2010 by Walter de Gruyter • Berlin • New York. DOI 10.1515/CCLM.2010.243 2010/698 Article in press - uncorrected proof Carcinoembryonic antigen concentrations in patients with acute coronary syndrome Cristina Vassalle*, Lorenza Pratali, Rudina Ndreu, Debora Battaglia and Maria Grazia Andreassi Fondazione G. Monasterio CNR-Regione Toscana and Institute of Clinical Physiology-CNR, Pisa, Italy Abstract Background: Carcinoembryonic antigen (CEA), one of the most widely used tumor markers, has been recently associ- ated with

References [1] Members WG, Roger VL, Go AS, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125: e2-220. [2] Knight CJ, Timmis AD. Almanac 2011: acute coronary syndromes. The national society journals present selected research that has driven recent advances in clinical cardiology. Heart 2011;97:1820-7. [3] Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010;362:2155-65. [4] Nolan JP, Lyon RM, Sasson C, et al

References 1. Dorobantu M, Tautu OF, Fruntelata A, et al – Hypertension and acute coronary syndromes in Romania: data from the ISACS-TC registry. Eur Heart J Suppl. 2014;16:A20-A27. 2. Kim JH, Chae SC, Oh DJ, et al – Multicenter cohort study of acute myocardial infarction in Korea—interim analysis of the Korea acute myocardial infarction registry-national institutes of health registry. Circ J. 2016;80:1427-1436. 3. Fresco C, Avanzini F, Bosi S, et al – Prognostic value of a history of hypertension in 11,483 patients with acute myocardial infarction treated with

REFERENCES 1. World Health Organization. Cardiovascular diseases (CVDs), 2017. Available from: http://www.who.int/mediacentre/factsheets/fs317/en/ . 2. Opolski MP, Kępka C, Rużyłło W. Computed tomography for detection of vulnerable coronary plaque – A Cassandra’s dream? Postępy w Kardiologii Interwencyjnej/Advances in Interventional Cardiology . 2014;10:147-152. 3. Choy SY, Mintz GS. What have we learned about plaque rupture in acute coronary syndromes? Curr Cardiol Rep . 2010;12:338-343. 4. Lafont A. Basic aspects of plaque vulnerability. Heart . 2003

, Herlitz J et al. Early Cardiopulmonary Resuscitation in Out-of-Hospital Cardiac Arrest. New Eng J Med. 2015;372:2307-2315. 4. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2015; pii: ehv320. [Epub ahead of print] 5. Collinson J, Flather MD, Fox KA, et al. Clinical outcomes

References 1 Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91:2844–50. 2 Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kDa gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91:2125–31. 3 Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94:2493–503. 4 Goldstein JA, Demetriou D

REFERENCES 1. Kamceva G, Vavlukis M, Kitanoski D, Kedev S. Newly Diagnosed Diabetes and Stress Glycaemia and Its’ Association with Acute Coronary Syndrome. Open Access Maced J Med Sci 2015; 3(4): 607-12. 2. AlNemer KA. Important high light on diabetes in acute coronary syndrome cases: Saudi Arabia. Integrative Molecular Medicine 2016; Volume 3(2): 562-3. 3. Lugg ST, May CJK, Nightingale P, et al. HbA1c screening for new onset diabetes following acute coronary syndrome: is it a worthwhile test in clinical practice? Journal of Diabetes & Metabolic Disorders 2017

Introduction Biochemical assays based on cardiac troponin T (cTnT) and I (cTnI) have become the gold standard for the diagnosis and risk prediction of patients with acute coronary syndromes (ACS) and myocardial necrosis [ 1 ]. The latest generation of high-sensitivity cTn immunoassays (hs-cTn) is even superior in terms of their improved diagnostic ability to detect early and even subtle, yet clinically important changes in circulating cTn [ 2 ]. Combining this superior sensitivity with dynamic changes over time allows early rule-in as well as rule-out of patients

References 1. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959–69. 2. Christenson RH, Duh SH, Sanhai WR, Wu AH, Holtman V, Painter P, et al. Characteristics of an Albumin Cobalt Binding test for assessment of acute coronary syndrome patients: a multicenter study. Clin Chem 2001; 47:464–70. 3. Alhadi HA, Fox KA. Do we need additional markers of myocyte